← Leaderboards
Pablo Perez-Pinera
University Of Illinois At Urbana-Champaign
$4,542,819
Attributed
$7,660,777
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,660,777 · 4
By mechanism
U01$4,091,010 · 1
R01$3,426,369 · 2
R03$143,398 · 1
Top collaborators
- Thomas Gaj6 shared
- Jun S Song4 shared
Most similar at University Of Illinois At Urbana-Champaign
Same institution · by research overlap
- Thomas Gaj$3,595,003
Others in their field
Other Emerging Leaders on “Gene Therapy”
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$26,358,801
- George Mitra · Leidos Biomedical Research, Inc.$23,876,869
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
Research focus
Gene TherapyGenesTechnologySpecificityMutationInnovationCellsNucleaseIn VivoBaseAmyotrophic Lateral SclerosisProgramsProteinsLeadImmune ResponseGenomic DnaSite-Directed MutagenesisEngineeringFutureCrispr/Cas TechnologyModificationBiotechnologySiteVariant
Grant awards (16)
Optimization of an in vivo base editing strategy to treat SOD1-linked ALS$993,968
U01 · FY2025 · NS
Optimization of an in vivo base editing strategy to treat SOD1-linked ALS$129,300
U01 · FY2025 · NS
Optimization of an in vivo base editing strategy to treat SOD1-linked ALS$1,093,040
U01 · FY2024 · NS
Development of Technologies for Efficient In Vivo Prime Editing$536,345
R01 · FY2024 · GM · contact PI
Optimization of an in vivo base editing strategy to treat SOD1-linked ALS$151,047
U01 · FY2024 · NS
Optimization of an in vivo base editing strategy to treat SOD1-linked ALS$853,800
U01 · FY2023 · NS
Development of Technologies for Efficient In Vivo Prime Editing$536,345
R01 · FY2023 · GM · contact PI
Optimization of an in vivo base editing strategy to treat SOD1-linked ALS$869,855
U01 · FY2022 · NS
Development of Technologies for Efficient In Vivo Prime Editing$536,345
R01 · FY2022 · GM · contact PI
Development of Technologies for Efficient In Vivo Prime Editing$535,871
R01 · FY2021 · GM · contact PI
Engineering platforms for editing RNA with single base resolution$319,620
R01 · FY2021 · GM · contact PI
Engineering platforms for editing RNA with single base resolution$320,127
R01 · FY2020 · GM · contact PI
Engineering platforms for editing RNA with single base resolution$320,619
R01 · FY2019 · GM · contact PI
Engineering platforms for genome-scale screening of transcriptional activation domains$71,587
R03 · FY2019 · EB · contact PI
Engineering platforms for editing RNA with single base resolution$321,097
R01 · FY2018 · GM · contact PI
Engineering platforms for genome-scale screening of transcriptional activation domains$71,811
R03 · FY2018 · EB · contact PI